As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.
Shares in innovative biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are rising 3% to $2.06 in today’s trading on the news that the company has …
H.C.
Risk-taker Dmitry Balyasny eyes advantage in the biotech world, between new initiations in TEVA, SGYP, and a major increase in OPK.
Shares in gastrointestinal biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are plunging by 30% this week, following the announcement of an equity offering to raise money. …
Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.
By Bret Jensen Small biotech stocks especially ‘Tier 3‘ concerns like Omeros and Flexion Therapeutics have been taking it on the shin for most …
This market-beating fund manager is slashing ACRX and SGYP, but upping ATRS.
